ABCL$3.61
$3.7004
Chart
Performance
Key Stats
AI ABCL Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAbCellera Biologics Inc. demonstrates solid financial health and promising growth potential within the biotechnology sector, supported by its innovative approach to drug discovery. While current technical indicators suggest a neutral to slightly bearish short-term outlook, its long-term prospects remain positive.
Thematic
AbCellera operates in the rapidly advancing field of antibody-based drug discovery, a significant thematic trend. The company's focus on unmet medical needs and its partnerships with major pharmaceutical players position it well within this high-growth sector.
Fundamental
AbCellera demonstrates robust financial health with significant cash reserves and manageable debt. While revenue and profitability have been inconsistent, the company is actively investing in growth, and its balance sheet provides a strong foundation.
Technical
The stock is trading below key moving averages and oscillators are mostly neutral to bearish, suggesting a lack of immediate upward momentum. However, the 52-week range indicates potential for recovery.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Partnerships & Collaborations | 80 |
| Drug Pipeline Advancement | 70 |
| Healthcare Demand | 75 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 25 |
| Balance Sheet Health | 95 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 60 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Moving Averages (Short-term) | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (12)
Positive Short-Term Performance
The stock has seen a positive performance of 16.72% over the last month and 30.07% over the last six months.
Positive Beta
The stock has a beta of 0.36, indicating lower volatility compared to the overall market.
Bearish Points (21)
Negative Price Change
The stock experienced a decrease of -0.07999992 (-1.9704415%) in its current price.
Negative EPS Estimates
Recent EPS estimates for Q2 2025 and Q1 2025 are negative (-0.14 and -0.15 respectively), indicating expected losses.
Calendar
August 2025
8
Next Earnings Date
H: $-0.14
A: $-0.16
L: $-0.19
H: 21.06M
A: 7.55M
L: 4.67M
Profile
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Seasonals
Price Target
8.43 USD
The 39 analysts offering 1 year price forecasts for ABCL have a max estimate of 17.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
As AbCellera's primary large pharma partner, Eli Lilly collaborated closely on the discovery and development of bamlanivimab, the successful COVID-19 antibody, representing a direct and significant commercial link.
Weight: 90
A major biopharmaceutical company with extensive expertise and proprietary platforms in antibody discovery and development, making them a direct competitor and peer in the field of platform-driven antibody generation.
Weight: 88
A biotechnology company focused on creating and developing differentiated antibody therapeutics using its own proprietary technology platforms (e.g., DuoBody, HexaBody), positioning them as a strong peer and competitor in innovative antibody development.
Weight: 85
A German biopharma company with a significant focus on therapeutic antibodies, known for its HuCAL antibody library and proprietary discovery technologies, making them a direct competitor and peer in the antibody platform space.